Background
Methods
Study design
Patients
Data collection
Pulmonary rehabilitation (PR) program
Statistical analysis
Results
Attendance and adherence to home-based PR
Variables | |
---|---|
Age (mean ± SD, years) | 60.6 ± 8.8 |
Gender (%) | |
Male | 76.1 (n = 54) |
Female | 23.9 (n = 17) |
BMI (mean ± SD, kg/m2) | 25.8 ± 8.8 |
Smokers (%) | |
Current smokers | 14.1 (n = 10) |
Former smokers | 56.3 (n = 40) |
Non smokers | 29.6 (n = 21) |
Type of thoracic cancer (%) | |
Adenocarcinoma | 42.3 (n = 30) |
Squamous cell carcinoma | 16.9 (n = 12) |
Small cell carcinoma | 5.6 (n = 4) |
Mesothelioma (MPM) | 23.9 (n = 17) |
Others | 11.3 (n = 8) |
Lung cancer TNM stage (%) excluding MPM | |
stage IB | 1.9 (n = 1) |
stage IIA | 5.6 (n = 3) |
stage IIB | 3.7 (n = 2) |
stage IIIA | 16.7 (n = 9) |
stage IIIB | 11.1 (n = 6) |
stage IV | 61.1 (n = 33) |
VSRQ total score (mean ± SD) | 46.3 ± 17 |
HAD scale | |
Anxiety score (median + IQR) | 7 [5–10] |
Depression score (median + IQR) | 6 [3–10] |
Baseline assessment before home-based PR
6MWT distance (m) | 6MST steps (nb) | TUG time (s) | 10CS time (s) | |
---|---|---|---|---|
All evaluated patients together | 390 [290–450] | 466 [297–572] | 9 [7–14] | 31 [25–47] |
Lung cancer stage | ||||
stage II | 440 [395–493] | 496 [412–516] | 13 [11–14] | 43 [27–59] |
stage III | 393 [323–433] | 482 [372–578] | 6 [5–8] | 25 [25–25] |
stage IV | 342 [260–460] | 441 [271–552] | 10 [8–15] | 36 [27–54] |
MPM | 445 [420–510] | 479 [337–582] | 8 [7–9] | 24 [21–33] |
WHO performance status | ||||
stage 0 (n = 24) | 430 [385–463] | 516 [455–596] | 6 [6–12] | 23 [18–28] |
stage 1 (n = 25) | 358 [285–440] | 468 [292–572] | 9 [7–14] | 31 [24–50] |
stage 2 (n = 21) | 290 [240–420] | 282 [148–404] | 9 [8–15] | 36 [27–47] |
mMRC dyspnea stage | ||||
stage 0 (n = 4) | 460 [448–473] | 672 [575–676] | NA | NA |
stage 1 (n = 26) | 430 [358–470] | 496 [408–579] | 8 [7–10] | 25 [21–29] |
stage 2 (n = 17) | 368 [250–435] | 542 [466–606] | 9 [6–11] | 30 [19–40] |
stage 3 (n = 9) | 285 [240–290] | 251 [150–276] | 10 [9–14] | 39 [31–48] |
stage 4 (n = 5) | 275 [170–380] | 132 [71–303] | 16 [11–23] | 54 [38–59] |
6MWT distance (m) | 6MST steps (nb) | TUG time (s) | 10CS time (s) | |
---|---|---|---|---|
Lung cancer stage | NS | NS | NS | NS |
WHO performance status | r = − 0.45, p = 0.001 | r = − 0.49, p < 0.001 | NS | r = 0.45, p = 0.007 |
mMRC dyspnea stage | r = − 0.50, p < 0.001 | r = − 0.50, p < 0.001 | NS | r = 0.51, p = 0.004 |
VSRQ total score | r = 0.36, p = 0.018 | r = 0.41, p = 0.002 | NS | r = − 0.36, p = 0.03 |
HAD total score | NS | r = − 0.28, p = 0.04 | NS | r = 0.35, p = 0.04 |
Evolution after home-based PR
Before PR | After PR | p-value | |
---|---|---|---|
6MWT distance (m) | 435 [356–461] | 433 [365–450] | NS |
6MST steps (nb) | 455 [305–574] | 493 [339–609] | 0.02 |
TUG time (s) | 9 [8–13] | 8.5 [7–10] | 0.054 |
10CS time (s) | 27 [24–51] | 25 [20–33] | 0.04 |
VSRQ total score | 46 [37–57] | 53 [39–62] | 0.06 |
HAD total score | 11 [8–17] | 10 [7–17] | 0.054 |
Anxiety score | 7 [5–10] | 6 [3–8] | 0.03 |
Depression score | 4 [3–9] | 5 [2–9] | NS |
PS 0 n = 16 | PS 1 n = 15 | PS 2 n = 15 | |
---|---|---|---|
6MWT distance (m) | 0 [−50, 43] | + 5 [− 20, 57] | − 90 [− 185, − 39] |
6MST steps (nb) | + 74 [2, 147] | + 96 [52, 113] | + 8 [− 10, 36] |
TUG time (s) | 0 [− 1, 1] | − 2 [− 2, − 2] | − 1 [− 3, 0] |
10CS time (s) | +3 [− 1, 4] | −6 [− 9, 0] | −4 [− 10, − 1] |
VSRQ total score | + 4 [− 10, 9] | + 4 [− 5, 13] | + 4 [2, 9] |
HAD total score | 0 [−5, 1] | −3 [− 7, 0] | 0 [− 3, 3] |
Anxiety score | −1 [− 3, 0] | −1 [− 3, 1] | 0 [− 2, 2] |
Depression score | 0 [−2, 1] | −2 [− 3, 1] | 0 [− 3, 3] |